Originally from FORBES article.
Cannabidiol, or CBD, seems to be everywhere these days. Trendy lunch spots are drizzling CBD oil on salads, bartenders and mixologists are adding it to cocktails, juice bars are adding it to their smoothies alongside wheatgrass and ginger, and coffee shops are adding it to their lattes. Even Bon Appetit is adding it to their arsenal of ingredients, promoting recipes like CBD Caramel Sauce, which they suggest serving “over ice cream, stirred into yogurt, or drizzled over a brownie or slice of pound cake.”
That’s a lot of hype for a compound that is one of more than a hundred cannabinoids found in the cannabis plant, and for one that causes absolutely no psychoactive effects. After all, for decades, psychoactive effects have been what many cannabis users have sought, leading to strains that had been specifically bred to diminish the amount of naturally occurring CBD.
Many people, though, have found CBD to be helpful in providing relief for a wide range of symptoms, including chronic pain, anxiety, inflammation, gut disorders, and neurological conditions. And last January, the Food and Drug Administration (FDA) approved Epidiolex, a CBD oral solution, as a treatment for seizures associated with two rare and severe forms of epilepsy.
While this application has been approved for a very specific and limited use, further research and clinical trials may lead to approval for other drugs and for other uses. In the 2018 Farm Bill, Congress removed hemp from the drug schedules outlined in the Controlled Substances Act, legalizing it under federal law. But even though this made CBD derived from hemp legal, it was still subject to FDA regulations when used in applications under the FDA’s purview. What this means, most notably, is that selling CBD as a food additive or dietary supplement gets tricky.
So how do companies respond to market demands while also not getting themselves crosswise with federal regulators?
We saw one solution recently, as the two biggest pharmacy chains in the United States decided that CBD was worth exploring. Both CVS and Walgreens announced – within days of each other – that they would begin selling hemp-derived CBD products in 2,300 stores between the two nationwide chains. While you won’t find the trendy CBD products listed above at these drugstores, their shelves will soon contain a variety of topical applications like creams, lotions, salves, patches, and sprays.
Let’s be clear here: this is a big step and a major development for the cannabis industry. The fact that nationally recognized brands are putting their weight behind cannabis-tangential products is almost certainly a harbinger of things to come – even if the complex reality of FDA regulations forces the drugstore chains to limit their CBD product lines to topical applications for practical and legal reasons.
In a December 20, 2018 statement after the signing of the Farm Bill, FDA Commissioner Scott Gottlieb asserted as much, saying “It’s unlawful under the [Federal Food, Drug, and Cosmetic Act] to introduce food or food containing added CBD or THC into interstate commerce, or to market CBD or THC products as, or in, dietary supplements, regardless of whether the substances are hemp-derived. This is because both CBD and THC are active ingredients in FDA-approved drugs and were the subject of substantial clinical investigations before they were marketed as foods or dietary supplements.”
This means that before we see these chains really double down on the new cannabis landscape, a new regulatory framework will have to be developed and implemented, providing guidance for what they can – and, importantly, what they can’t – do. We may still be a long way off from that framework coming into place, but as with other developments, it is encouraging to see a willingness to explore and take action where possible.
What we do know is that the demand is there. Until the regulations catch up, retailers looking to test the market may find lotions and salves to be a safer bet. And if consumers meet or exceed retailers’ projections, then we will almost certainly see other retailers follow suit.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
The statements made regarding these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. The efficacy of these products has not been confirmed by FDA-approved research. Information presented here is not meant to substitute information from a licensed health care practitioner. Please consult your healthcare professional about potential interactions or other possible complications before using our products. Simple Garden™ CBD assumes no responsibility for the improper use of our products. We do not make any health claims about our products. Results from the use of Simple Garden™ CBD products may vary depending upon the individual, and we make no guarantee as to the results that you may experience. If you are pregnant, nursing, chronically ill, elderly or under the age of 18 please consult a qualified physician prior to consuming. You must be 18 years or older to visit this website and/or purchase Simple Garden™ CBD products. All information on our website is intended to provide general information regarding our products, and should not considered medical advice. The Federal Food, Drug, and Cosmetic Act requires this notice.